<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203823</url>
  </required_header>
  <id_info>
    <org_study_id>CIP326</org_study_id>
    <nct_id>NCT04203823</nct_id>
  </id_info>
  <brief_title>Feasibility Studies of Personalized Closed Loop</brief_title>
  <official_title>Feasibility Study With Personalized Closed Loop (PCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm study comprised of a series of feasibility studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Feasibility Study Part 2 (i.e. Feasibility 2): Feasibility 2 is the focus of the current&#xD;
      version of the study protocol.&#xD;
&#xD;
      This study will include 2 separate Cohorts of individuals, based on the algorithms being&#xD;
      studied:&#xD;
&#xD;
      Cohort A: The main purpose of this cohort is to test the Digital Twin insulin delivery&#xD;
      algorithm adaptation&#xD;
&#xD;
      Cohort C: The main purpose of this cohort is to test a meal prediction algorithm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Arm (Cohort) assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Severe Hypoglycemic Event - Cohort A</measure>
    <time_frame>approximately 3.5 months</time_frame>
    <description>Number of severe hypoglycemic events occurred in the study in Cohort A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Diabetic Ketoacidosis (DKA) Event - Cohort A</measure>
    <time_frame>approximately 3.5 months</time_frame>
    <description>Number of Diabetic Ketoacidosis (DKA) event occurred in the study in Cohort A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of time in Euglycemia - Cohort A</measure>
    <time_frame>approximately 3.5 months</time_frame>
    <description>The overall mean percentage of time in Euglycemia (70-180 mg/dL) in Cohort A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Severe Hypoglycemic Event - Cohort C</measure>
    <time_frame>approximately 3.5 months</time_frame>
    <description>Number of severe hypoglycemic events occurred in the study in Cohort C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Diabetic Ketoacidosis (DKA) Event - Cohort C</measure>
    <time_frame>approximately 3.5 months</time_frame>
    <description>Number of Diabetic Ketoacidosis (DKA) event occurred in the study in Cohort C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of time in Euglycemia - Cohort C</measure>
    <time_frame>approximately 3.5 months</time_frame>
    <description>The overall mean percentage of time in Euglycemia (70-180 mg/dL) in Cohort C</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Algorithm Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The main purpose of this cohort is to test the Digital Twin insulin delivery algorithm and the Meal Prediction algorithm&#xD;
The study population will be enrolled as 2 separate cohorts to test each algorithms individually</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cloud-based Digital Twin and Meal Prediction algorithms</intervention_name>
    <description>Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms</description>
    <arm_group_label>Algorithm Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria&#xD;
&#xD;
          1. Subject is age 2-80 years at time of Visit 1. Note: See staged enrollment reference&#xD;
             for adult and pediatric subjects in the Study Design section&#xD;
&#xD;
          2. Subject has a clinical diagnosis of type 1 diabetes.&#xD;
&#xD;
               1. Subjects 7 years of age and older: Diagnosed at least 1 year prior to Visit 1&#xD;
&#xD;
               2. Subjects 2-6 years of age: Diagnosed at least 3 months prior to Visit 1&#xD;
&#xD;
             Study-specific inclusion criteria&#xD;
&#xD;
          3. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater&#xD;
             than or equal to 8 units.&#xD;
&#xD;
          4. If subject has a history of hypothyroidism, must have at least 1 documented normal&#xD;
             thyroid-stimulating hormone (TSH) on historical labs within 12 months of Visit 1. A&#xD;
             subject without a history of hyperthyroidism is not expected to have a TSH test&#xD;
&#xD;
          5. Subjects and their parent(s)/guardian(s) must have Internet access , a computer system&#xD;
             that meets the requirements for uploading the study pump and Smartphone that meets&#xD;
             study requirements.&#xD;
&#xD;
          6. Subject must have a companion or caregiver available at night for the duration of the&#xD;
             study period who resides (or will live) in in the same building (or home). This&#xD;
             requirement may be verified by subject report at screening visit.&#xD;
&#xD;
          7. If subject has celiac disease, it has been adequately treated as determined by the&#xD;
             investigator.&#xD;
&#xD;
          8. Subjects and their parent(s)/guardian(s) are willing to take one of the following&#xD;
             insulins and can financially support the use of either of the 2 insulin preparations&#xD;
             throughout the course of the study (i.e. co-payments for insulin with insurance or&#xD;
             able to pay full amount)&#xD;
&#xD;
               -  Humalog™* (insulin lispro injection)&#xD;
&#xD;
               -  NovoLog™* (insulin aspart)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in&#xD;
             any the following during the last 1 year prior to Visit 1&#xD;
&#xD;
               1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)&#xD;
&#xD;
               2. Coma&#xD;
&#xD;
               3. Seizures&#xD;
&#xD;
          2. Subject is unable to tolerate tape adhesive in the area of sensor placement.&#xD;
&#xD;
          3. Subject has any unresolved adverse skin condition in the area of sensor placement&#xD;
             (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).&#xD;
&#xD;
          4. Women of child-bearing potential who have a positive pregnancy test at Visit 1 or plan&#xD;
             to become pregnant during the course of the study&#xD;
&#xD;
          5. Females who are sexually active and able to conceive will be excluded if they are not&#xD;
             using an effective method of contraception and do not agree to continue using an&#xD;
             effective method of contraception for the duration of the study as determined by&#xD;
             investigator.&#xD;
&#xD;
          6. Subject has a cardiovascular condition which the Study Investigator determines should&#xD;
             exclude the subject, e.g. ventricular rhythm disturbance, hypertrophic cardiomyopathy,&#xD;
             recent myocardial infarction in the last year prior to Visit 1.&#xD;
&#xD;
          7. Subject is being treated for hyperthyroidism at time of Visit 1.&#xD;
&#xD;
          8. Subject has a diagnosis of adrenal insufficiency.&#xD;
&#xD;
          9. Subject has had Diabetic Ketoacidosis (DKA) within 1 year prior to Visit 1.&#xD;
&#xD;
         10. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8&#xD;
             weeks from time of visit 1, or plans to take any oral, injectable, or IV&#xD;
             glucocorticoids during the course of the study.&#xD;
&#xD;
         11. Subject is actively participating in an investigational study (e.g., drug or device)&#xD;
             wherein he/she has received treatment from an investigational study (drug or device)&#xD;
             in the last 2 weeks prior to Visit 1. Please note participation in observational study&#xD;
             is acceptable.&#xD;
&#xD;
         12. Subject has been hospitalized or has visited the ER in the 6 months prior to Visit 1&#xD;
             resulting in a primary diagnosis of uncontrolled diabetes.&#xD;
&#xD;
         13. Subject is currently abusing illicit drugs.&#xD;
&#xD;
         14. Subject is currently abusing alcohol.&#xD;
&#xD;
         15. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other&#xD;
             GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time&#xD;
             of Visit 1.&#xD;
&#xD;
         16. Subject has a history of visual impairment which would not allow subject to&#xD;
             participate in the study and perform all study procedures safely, as determined by the&#xD;
             investigator.&#xD;
&#xD;
         17. Subject has elective surgery planned that requires general anesthesia during the&#xD;
             course of the study.&#xD;
&#xD;
         18. Subject diagnosed with current eating disorder such as anorexia or bulimia.&#xD;
&#xD;
         19. Subject has been diagnosed with chronic kidney disease that results in chronic anemia.&#xD;
&#xD;
         20. Subject is on dialysis.&#xD;
&#xD;
         21. Subject has serum creatinine of &gt;2 mg/dL, as confirmed through historical labs within&#xD;
             1 year prior to Visit 1.&#xD;
&#xD;
         22. Subject is a member the research staff involved with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas P Troub</last_name>
    <phone>8185763142</phone>
    <email>thomas.troub@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Corrigan</last_name>
    <phone>818-5765849</phone>
    <email>carrie.corrigan@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Socal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center - Adults</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center / Pediatric</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida Diabetes Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Rodriguez</last_name>
      <phone>813-974-5499</phone>
      <email>janetrodriguez@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Shulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Solutions, Inc.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Park Nicollet International Diabetes Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

